XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4785-4790

  Cereda, Stefano ^a   Reni, Michele ^a   Rognone, Alessia ^a   Ghidini, Michele ^a   Belli, Carmen ^a   Longoni, Simona ^a   Fugazza, Clara ^a   Brioschi, Matteo ^a   Nicoletti, Roberto ^a   Balzano, Gianpaolo ^a   Passoni, Paolo ^a   Villa, Eugenio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

FOLFIRI; Gemcitabine resistant disease; Irinotecan; Pancreatic cancer; XELIRI

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINATE CALCIUM; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; STOMATITIS; VOMITING;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650253617     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997.
2. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E and Di Carlo V: Gemcitabine vs. cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 6: 369-376, 2005.
3. Reni M, Berardi R, Mambrini A, Pasetto L, Cereda S, Ferrari VD, Cascinu S, Cantore M, Mazza E and Grisanti S: A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 62: 673-678, 2008.
4. Boeck S, Weigang-Köhler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stötzer O, Zeuzem S, Lordick F, Köhne CH, Kröning H, Steinmetz T, Depenbrock H and Heinemann V: Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 18: 745-751, 2007.
5. Boeck S, Wilkowski R, Brans CJ, Issels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A and Heinemann V: Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 73: 221-227, 2007.
6. Cereda S, Reni M, Rognone A, Fugazza C, Ghidini M, Ceraulo D, Mazza E, Nicoletti R, Villa E and Reni M: Salvage therapy with mitomycin and ifosfamide (MI) in patients with gemcitabine-resistant metastatic pancreatic cancer. Ann Oncol 19: abstract 577, 2008.
7. Burris HA 3rd, Rivkin S, Reynolds R, Harris J, Wax A, Gerstein H, Mettinger KL and Staddon A: Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 10: 183-190, 2005.
8. Ulrich-Pur H, Raderer M, Verena Kornek G, Schüll B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F and Scheithauer W: Irinotecan plus raltitrexed vs. raltitrexed alone in patients with gemcitabine-pretreated advanced adenocarcinoma. Br J Cancer 88: 1180-1184, 2003.
9. Cereda S and Reni M: Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother 20: 509-512, 2008.
10. Oettle H, Arnold D, Esser M, Huhn D and Riess H: Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drags 11: 635-638, 2000.
11. Togawa A, Yoshitomi H, Ito H, Kimura F, Shimizu H, Ohtsuka M, Yoshidome H, Kato A, Sawada S and Miyazaki M: Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. Int J Clin Oncol 12: 268-273, 2007.
12. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C and Fuchs CS: Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25: 4787-4792, 2007.
13. Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E and Papalambros E: Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a Phase II Study. Invest New Drugs 23: 369-375, 2005.
14. Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A and Van Laethem JL: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94: 481-485, 2006.
15. Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C, Mambrini A, Del Freo A and Manni A: Combined irinotecan and oxalipatin in patients with advanced pre-treated pancreatic cancer. Oncology 67: 93-97, 2004.
16. Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C and Di Carlo V: PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol 31: 145-150, 2008.
17. Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaner I, Adler M, Detken S, Dörken B and Riess H: Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). Proc Am Soc Clin Oncol 16: abstract 4031, 2005.
18. Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell'Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo V and Brandes AA: Raltitrexed-eloxatin salvage chemotherapy in gemcitabine resistant metastatic pancreatic cancer. Br J Cancer 94: 785-791, 2006.
19. Mans DR, Grivicich I, Peters GJ and Schwartsmann G: Sequence-dependent growth inibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 35: 1851-1861, 1999.
20. Wagener DJ, Verdonk HE, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boué A and Verweij J: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6: 129-132, 1995.
21. Ueno H, Okusaka T, Funakoshi A, Ishii H, Yamao K, Ishikawa O, Ohkawa S and Saitoh S: A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 59: 447-454, 2007. (Pubitemid 46127378)
22. Skof E, Rebersek M, Hlebanja Z and Ocvirk J: Capecitabine plus irinotecan (XELIRI regimen) compare to 5-FU/LV plus irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC cancer 9: 120, 2009.
23. Guichard S, Hennebelle I, Bugat R and Canal P: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55: 667-676, 1998.
24. Cao S, Durrani FA and Rustum YM: Synergistic antitumor activity of capecitabine in combination with irinotecan. Clin Colorectal Cancer 4: 336-343, 2005.
25. Taïeb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, Fallik D, Spano JP, Landi B, Lledo G and Desrame J: FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 18: 498-503, 2007.
26. Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R, Mery-Mignard D, Cornen X, Mouri Z and Bugat R: A phase I clinical and pharmakinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer 92: 820-826, 2005.
27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
28. Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, Mazza E, Zerbi A, Di Carlo V and Villa E: Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 115: 2630-2639, 2009.
29. Ajani JA, Welch SR, Raber MN, Fields WS and Krakoff I: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8: 147-159, 1990.
30. Reni M, Cereda S, Passoni P, Rognone A, Mazza E, Passoni P, Nicoletti R, Arcidiacono PG, Zerbi A, Balzano G and Di Carlo V: A randomized phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 25: abstract 4628, 2007.
31. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr., Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and Miller LL: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increase tumor rate. J Clin Oncol 22: 3776-3783, 2004.
32. Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G and Georgoulias V: A multicenter phase III trial comparing irinotecan-gemcitabine with gemcitabine monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95: 587-592, 2006.
33. Markham C, Stocken DD and Hassan AB: A phase II irinotecan-cisplatin combination in advanced pancreatic cancer. Br J Cancer 89: 1860-1863, 2003.
34. Conroy T, Desseigne F, Ychou M, Ducreux M, Bouche O, Guimbaud R, Becouam Y, Montoto-Grillot C, Gourgou-Bourgade S, Adenis A; FNCLCC-FFCD PRODIGE Group: Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucoverin (LV), irinotecan (I), and oxaliplatin (O)) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol 28: abstract 4010, 2010
35. Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T and Kozuch P: Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucoverin and cisplatin in patients with metastatic pancreatic cancer. Anticancer Drugs 18: 263-271, 2007.
36. Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J and Murren JR: Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer. Cancer J 13: 257-262, 2007.
37. Shitara K, Komatsu Y, Yuki S, Munakata M, Muto O, Shimaya S and Sakata Y: Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer. Oncology 75: 67-70, 2008.
38. Endlicher E, Troppmann M, Kullmann A, Golder S, Herold T, Herfarth H, Grossmann J, Schlottmann K and Kullmann F: Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study. Oncology 72: 279-284, 2007.
39. Lipton A, Campbell-Baird C, Witters L, Harvey H and Ali S: Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 44: 286-288, 2010.
40. Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY and Kang WK: Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 63: 1141-1145, 2009.
41. Klapdor R and Fenner C: Irinotecan (Campto R): efficacy as third/fourth line therapy in advanced pancreatic cancer. Anticancer Res 20: 5209-5212, 2000.
42. Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P and Bruckner HW: Irinotecan combined with gemcitabine, 5-fluorouracil, leucoverin, and cisplatin (G-FLIP) is an active and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6: 488-495, 2001.
43. Reni M, Panucci MG, Passoni P, Bonetto E, Nicoletti R, Ronzoni M, Zerbi A, Staudacher C, Di Carlo V and Villa E: Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 22: 688-696, 2004.
44. Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC and Lee JL: A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101: 1658-1663, 2009.
45. Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C and Colucci G: Irinotecan plus bolus/infusional 5-fluorouracil and leucoverin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Oncol 33: 461-464, 2010